Veterinary Medicines

V.H. + H-120 - atenuowany wirus rzekomego pomoru ptaków (choroby Newcastle), szczep VHnie mniej niż 10^6,0 EID50 i nie więcej niż 10^7,49 EID50;- atenuowany wirus zakaźnego zapalenia oskrzeli ptaków, szczep H-120nie mniej niż 10^3,5 EID50 i nie więcej niż 10^4,49 EID50. Liofilizat do sporządzania zawiesiny

Authorised
  • Newcastle disease virus, strain V.H., Live
  • Avian infectious bronchitis virus, type Massachusetts, strain H120, Live
Download as PDF

Product identification

Medicine name:
V.H. + H-120 - atenuowany wirus rzekomego pomoru ptaków (choroby Newcastle), szczep VHnie mniej niż 10^6,0 EID50 i nie więcej niż 10^7,49 EID50;- atenuowany wirus zakaźnego zapalenia oskrzeli ptaków, szczep H-120nie mniej niż 10^3,5 EID50 i nie więcej niż 10^4,49 EID50. Liofilizat do sporządzania zawiesiny
Active substance:
  • Newcastle disease virus, strain V.H., Live
  • Avian infectious bronchitis virus, type Massachusetts, strain H120, Live
Target species:
  • Chicken (hen)
Route of administration:
  • Nebulisation use
  • In drinking water use

Product details

Active substance and strength:
  • Newcastle disease virus, strain V.H., Live
    30903000.00
    50% Embryo Infective Dose
    /
    1.00
    50% Embryo Infective Dose
  • Avian infectious bronchitis virus, type Massachusetts, strain H120, Live
    30903.00
    50% Embryo Infective Dose
    /
    1.00
    50% Embryo Infective Dose
Pharmaceutical form:
  • Lyophilisate for suspension
Withdrawal period by route of administration:
  • Nebulisation use
    • Chicken (hen)
      • All relevant tissues
        0
        day
  • In drinking water use
    • Chicken (hen)
      • All relevant tissues
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD06
  • QI01AD07
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Poland
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Well-established use application (Article 13a of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Phibro Animal Health (Poland) Sp. z o.o.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Synoptis Industrial Sp. z o.o.
Responsible authority:
  • Office For Registration Of Medicinal Products Medical Devices And Biocidal Products
Authorisation number:
  • 1232
Date of authorisation status change:

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 13/08/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 13/08/2024
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 13/08/2024
Download